{"id":196647,"name":"HALOZYME THERAPEUTICS, INC.","slug":"halozyme-therapeutics-inc","state":"CA","country":"United States of America","description":"U.S. Biotechnology Company","totalSpending":700000,"filings":27,"yearlySpending":[{"year":2019,"income":50000},{"year":2020,"income":30000},{"year":2021,"income":0},{"year":2022,"income":0},{"year":2023,"income":140000},{"year":2024,"income":240000},{"year":2025,"income":240000}],"issues":[{"code":"HCR","display":"Health Issues"},{"code":"MMM","display":"Medicare/Medicaid"},{"code":"SCI","display":"Science/Technology"},{"code":"BUD","display":"Budget/Appropriations"}],"firms":["FORBES-TATE"],"lobbyists":["ZACHARY WILLIAMS","ELIZABETH GREER","JEFFREY FORBES","JEFFREY STRUNK","FRANKLYN STEINBERG","DERRICK WHITE","EDWARD RENO","KRISTINA DUNKLIN","BARRETT THORNHILL","MICHAEL WILLIAMS"],"govEntities":["HOUSE OF REPRESENTATIVES","SENATE","Centers For Medicare and Medicaid Services (CMS)","Health & Human Services, Dept of (HHS)"],"sampleDescriptions":["Issues related to the coverage of and reimbursement for novel drug delivery system and market uptake/access","Issues related to the coverage of and reimbursement for novel drug delivery system and market uptake/access","Issues related to the coverage of and reimbursement for novel drug delivery system and market uptake/access","Issues related to the coverage of and reimbursement for novel drug delivery system and market uptake/access.","Issues related to the coverage of and reimbursement for novel drug delivery system and market uptake/access."]}